Erratum: Statins for Primary Prevention: The Debate Is Intense, But theData AreWeak (JAMA - Journal of the American Medical Association (2016) 316:19 (1979-1981) DOI: 10.1001/jama.2016.15085);Statins for primary prevention: The debate is intense, but the data are weak

JAMA - Journal of the American Medical Association

Volumn 316, Issue 19, 2016, Pages 1979-1981

  Redberg, Rita F ^a   Katz, Mitchell H ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DIABETES MELLITUS; DRUG LABELING; DRUG SAFETY; EDITORIAL; ELECTRONIC MEDICAL RECORD; EVIDENCE BASED MEDICINE; FATIGUE; HEALTH PROMOTION; HEART INFARCTION; HUMAN; LIFESPAN; MEDICAL DECISION MAKING; META ANALYSIS (TOPIC); MORTALITY; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NUTRITIONAL HEALTH; PEER REVIEW; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; SHARED DECISION MAKING; SIDE EFFECT; SMOKING CESSATION; SYSTEMATIC ERROR; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; UNITED STATES; UNSPECIFIED SIDE EFFECT; CARDIOVASCULAR DISEASES;

CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRIMARY PREVENTION;

EID: 85006124197     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2020.0372     Document Type: Erratum

References (19)

1. US Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. JAMA. doi:10.1001/jama.2016.15450
2. Chou R, Dana T, Blazina I, DaegesM, Jeanne TL. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US Preventive Services Task Force. JAMA. doi:10.1001/jama.2015.15629
3. Shepherd J, Cobbe SM, Ford I, et al;West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333(20):1301-1307.
4. Ray KK, Seshasai SRK, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: ameta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010;170(12):1024-1031.
5. Furberg CD, Adams HP Jr, Applegate WB, et al; Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 1994;90(4):1679-1687.
6. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2012;12: MR000033.
7. Chou R, Dana T, Blazina I, et al. Statins for Prevention of Cardiovascular Disease in Adults: Systematic Review for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2015. AHRQ publication 14-05206-EF-2.
8. Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statinmyopathy: A common dilemma not reflected in clinical trials. Cleve Clin J Med. 2011;78(6):393-403.
9. Cholesterol Treatment Trialists' (CTT) Collaboration. Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Am J Cardiol. 1995;75(16):1130-1134.
10. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25) (suppl 2):S1-S45.
11. WolfsonW. Playing the odds with statins: heart disease or diabetes? NPR website. http://www.npr.org/sections/health-shots/2015/03/10/390944811/playing-The-odds-with-statins-heart-disease-or-diabetes. Accessed October 4, 2016.
12. Mayo Clinic Shared Decision Making National Resource Center. Should I take statins? a decision making tool. Mayo Clinic website. http://shareddecisions.mayoclinic.org/files/2011/08/Statin-DA-avg21.pdf. Accessed October 11, 2016.
13. Stine NW, Chokshi DA. Elimination of lipid levels from quality measures: implications and alternatives. JAMA. 2014;312(19):1971-1972.
14. Preiss D, Seshasai SR,Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: ameta-analysis. JAMA. 2011;305(24):2556-2564.
15. US Food and Drug Administration (FDA). FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs. FDA website. http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm. Accessed November 1, 2016.
16. Johansen ME, Green LA. Statin use in very elderly individuals, 1999-2012. JAMA Intern Med. 2015;175(10):1715-1716.
17. Sugiyama T, Tsugawa Y, Tseng C-H, Kobayashi Y, Shapiro MF. Different time trends of caloric and fat intake between statin users and nonusers among US adults: gluttony in the time of statins? JAMA Intern Med. 2014;174(7):1038-1045.
18. Herper M. As statins soar, use of other cholesterol medicines declines. Forbes.May 29, 2013. http://www.forbes.com/sites/matthewherper/2013/05/29/as-statins-soar-use-of-other-cholesterol-medicines-declines/#2f08a4081186. Accessed October 13, 2016.
19. PRNewswire. Statins market to 2018-weak product pipeline and shift of focus towards combination therapies will lead to erosion of brand share. PRNewswire website. http://www.prnewswire.com/news-releases/statins-market-to-2018--weak-product-pipeline-and-shift-of-focus-towards-combination-therapies-will-lead-to-erosion-of-brand-share-217419941.html. July 29, 2013. Accessed October 13, 2016.